RFG Advisory’s BioCryst Pharmaceuticals BCRX Stock Holding History

RFG Advisory’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-2,870,700	Closed	-$27.3M	–	1135
2026 Q1	$27.3M	Buy	+2,870,700	New	+$22.3M	0.5%	26

Other funds holding BCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Jupiter Topco New York $245B AUM

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

RFG Advisory's BCRX Position: Q2 2026 in Review

RFG Advisory sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2026, closing a stake of 2,870,700 shares — an estimated $27.3M sold.

RFG Advisory first reported a position in BCRX in Q1 2026 and held it in 1 quarter. The position peaked at $27.3M in Q1 2026. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

RFG Advisory reported no remaining BioCryst Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
RFG Advisory sold 2,870,700 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $27.3M.
RFG Advisory first reported a position in BioCryst Pharmaceuticals in Q1 2026 and held it in 1 quarter.
RFG Advisory's BioCryst Pharmaceuticals position peaked at $27.3M in Q1 2026.
318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on RFG Advisory's 13F filing for Q2 2026, filed 15 Jul 2026.